Cargando…
Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1
OBJECTIVE: To investigate Tau pathology using multimodal biomarkers of neurodegeneration and neurocognition in participants with myotonic dystrophy type 1 (DM1). METHODS: We recruited twelve participants with DM1 and, for comparison, two participants with Alzheimer’s Disease (AD). Participants under...
Autores principales: | Laforce, Robert Jr, Dallaire-Théroux, Caroline, Racine, Annie M., Dent, Gersham, Salinas-Valenzuela, Cristian, Poulin, Elizabeth, Cayer, Anne-Marie, Bédard-Tremblay, Daphnée, Rouleau-Bonenfant, Thierry, St-Onge, Frédéric, Schraen-Maschke, Susanna, Beauregard, Jean-Mathieu, Sergeant, Nicolas, Puymirat, Jack |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217820/ https://www.ncbi.nlm.nih.gov/pubmed/35103843 http://dx.doi.org/10.1007/s00415-022-10970-x |
Ejemplares similares
-
iPSC-derived cardiomyocytes from patients with myotonic dystrophy type 1 have abnormal ion channel functions and slower conduction velocities
por: Poulin, Hugo, et al.
Publicado: (2021) -
Neurocognitive Features of Motor Premanifest Individuals With Myotonic Dystrophy Type 1
por: van der Plas, Ellen, et al.
Publicado: (2021) -
RBFOX1 Cooperates with MBNL1 to Control Splicing in Muscle, Including Events Altered in Myotonic Dystrophy Type 1
por: Klinck, Roscoe, et al.
Publicado: (2014) -
Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1
por: De Serres-Bérard, Thiéry, et al.
Publicado: (2022) -
Relationships between grip strength, myotonia, and CTG expansion in myotonic dystrophy type 1
por: Hogrel, Jean‐Yves, et al.
Publicado: (2017)